CompoAtlas

PMK 040 Tab Relieves Abdominal Pain

Natural health product licensed in Canada

Licence holder
PMK Federal Regulatory Consultants Ltd.
NPN or DIN-HM
80037051
Status
Active licence
Licence date
31 October 2012
Revision date
Not provided
Form
Comprimé
Route of administration
Orale
Application type
Non traditionnelle

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Trigonella foenum-graecum

Source : Trigonella foenum-graecum-Seed

Extraction ratio : 20:1

Dry plant equivalent : 2,000 mg

100 mgNot calculated
Matricaria chamomilla

Source : Matricaria chamomilla, fleur

Extraction ratio : 10:1

Dry plant equivalent : 1,500 mg

150 mgNot calculated
Glycyrrhiza glabra

Source : Glycyrrhiza glabra - racine

Extraction ratio : 10:1

Dry plant equivalent : 600 mg

60 mgNot calculated

Non-medicinal ingredients

Acide stéarique, Stéarate de magnésium, Cellulose microcristalline, Eau purifiée, Dioxyde de silicium

PopulationAgeQuantity per servingFrequency
AdultesNot specifiedminimum: 1 Comprimé ; maximum: 2 Compriméminimum: 1 Tous les jours ; maximum: 3 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Used in Herbal Medicine to help relieve inflammatory conditions of the gastrointestinal tract, such as gastritis in adults. Gastritis is an inflammation of the lining of the stomach, causing pain or discomfort in the upper abdomen. Used in Herbal Medicine to help relieve inflammatory conditions of the gastrointestinal tract. Used in Herbal Medicine to help relieve dyspepsia and gastritis. Gastritis is an inflammation of the lining of the stomach, causing pain or discomfort in the upper abdomen.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80037051

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Trigonella foenum-graecum
    Read the warning, when it applies and the studies cited

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 29 May 2026

  • Matricaria chamomilla
    Read the warning, when it applies and the studies cited

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral

    Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).

    Cautions and warnings

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

    German Chamomile - Matricaria Chamomilla Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 31 January 2025

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal

    Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)

    Cautions and warnings

    Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

  • Glycyrrhiza glabra
    Read the warning, when it applies and the studies cited

    DEGLYCYRRHIZINATED LICORICE Buccal

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 October 2025

    Deglycyrrhizinated Licorice Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 January 2025

    LICORICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Cough relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Gastritis relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant (EMA 2012).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line